The BABIES study is a single-center, randomized, double-blinded, placebo-controlled study in newborns with a 4-week intervention period from birth to 28 days of life followed by a 2-week follow-up period (Figure 1). The study will evaluate the seeding ability of supplementation with a probiotic strain.
The aim is to investigate the recovery and engraftment of the probiotic strain in infant fecal samples after 4 weeks supplementation using a strain specific quantitative Polymerase Chain Reaction (qPCR).

开始日期2025-03-04

申办/合作机构

Hvidovre University Hospital

[+1]

NCT06631937

/ RecruitingN/AIIT

The Effect of Human Milk Oligosaccharides on Infant Gut Microbiota Modulation, Development of the Immune System and Health Later in Life: the BELIEF Study

The goal of this clinical trial is to learn how a mixture of human milk oligosaccharides impacts the development of the infant microbiota, the immune maturation and how the interaction between the microbiota and immune maturation may impact both short and long term health of the infant.
The participants will:
* Consume the investigational products (active/placebo) for 6 months
* Legal guardians/parents to the participant to collect stool samples from the diapers at home
* Legal guardians/parents to the participant to report gastrointestinal symptoms, signs of infections in an electronic questionnaire
* Visit the clinic for checkups and dried blood sample collection
For reference, a group of breastfed infants will be included. They will undergo the same procedures apart from consuming the investigational product (active/placebo). 230 participants (115 in each intervention arm) will be randomized to an intervention and 104 participants will be recruited for the reference group, giving a total sample size of 334 participants.
The intervention trial will be reported in two steps, first step covering the intervention phase from birth to 6 months; and step two includes both the intervention phase (0-6 months) and the follow-up period from 6-12 months. Informed consents for the possibility to preform long-term follow-up will be obtained.

开始日期2024-11-05

申办/合作机构

University of Aarhus

[+3]

NCT06107088

/ CompletedN/A

A Proof-of-concept Study to Evaluate the Effect and the Tolerability of a Novel Combination of Lactase Enzyme and Ligilactobacillus Salivarius DSM 34078 in Individuals With Lactose Intolerance

The goal of this clinical trial is to test whether a new combination of lactase and bacterial strain (L. Salivarius DSM 34078) can provide longer lasting beneficial effects on lactose digestion and gastrointestinal symptoms compared to lactase alone in people with lactose intolerance.

开始日期2023-11-20

申办/合作机构

Novozymes A/S

[+1]

100 项与 Novozymes A/S 相关的临床结果

登录后查看更多信息

0 项与 Novozymes A/S 相关的专利（医药）

登录后查看更多信息

1,608

项与 Novozymes A/S 相关的文献（医药）

2025-03-01·Nature Chemical Biology

Engineering a xylose fermenting yeast for lignocellulosic ethanol production

Article

作者: Jiang, Yu ; Yang, Sheng ; Wu, Wen-Ping ; Zhang, Yi-Wen ; Sutton, Kate Brandon ; Hjort, Carsten ; Yang, Jun-Jie ; Qian, Feng-Hui

Lignocellulosic ethanol is produced by yeast fermentation of lignocellulosic hydrolysates generated by chemical pretreatment and enzymatic hydrolysis of plant cell walls. The conversion of xylose into ethanol in hydrolysates containing microbial inhibitors is a major bottleneck in biofuel production. We identified sodium salts as the primary yeast inhibitors, and evolved a Saccharomyces cerevisiae strain overexpressing xylose catabolism genes in xylose or glucose-mixed medium containing sodium salts. The fully evolved yeast strain can efficiently convert xylose in the hydrolysates to ethanol on an industrial scale. We elucidated that the amplification of xylA, XKS1 and pentose phosphate pathway-related genes TAL1, RPE1, TKL1, RKI1, along with mutations in NFS1, TRK1, SSK1, PUF2 and IRA1, are responsible and sufficient for the effective xylose utilization in corn stover hydrolysates containing high sodium salts. Our evolved or reverse-engineered yeast strains enable industrial-scale production of lignocellulosic ethanol and the genetic foundation we uncovered can also facilitate transfer of the phenotype to yeast cell factories producing chemicals beyond ethanol.

2024-09-14·Journal of Animal Science

157 Microbial inoculant effects on limpograss silage

作者: Moriel, Philipe ; Vendramini, Joao M B ; da silva, Hiran ; Sinisicalchi, Debora ; Lazarin, Joao V L ; Miranda, Andre ; Cappellozza, Bruno I

AbstractWarm-season perennial grasses are the main forage sources preserved as silage or haylage by livestock producers in subtropical and tropical regions; however, the nutritive value and silage fermentation parameters are often less than desirable. Microbial inoculants have been used to improve grass silage nutritive value and fermentation characteristics with inconsistent results. The objective of this study was to investigate the effects of a microbial inoculant on nutritive value and fermentation parameters of ‘Gibtuck’ limpograss (Hemarthria altissima) silage. Treatments were silage treated with SiloSolve FC (68.1 billion CFU/g, Lactobacillus lactis and Lactobacillus buchneri) or control (no microbial inoculant) distributed in a complete randomized design with 10 replicates. The inoculant level used was 0.5 g/Mg of forage. The experiment was conducted in Ona, FL in May 2023. Twenty 4 × 4 m plots of established limpograss were harvested at 15-cm stubble height with 58-d regrowth interval. The forage was chopped to a particle size ranging from 10 to 18 mm, placed into mini-silos (PVC pipes with rubber), and sealed immediately. The inoculant was applied with a hand sprayer before ensiling. The silos were opened after 60 d for analysis. There was no difference (P > 0.05) between the inoculant and control treatments on DM concentration (25%), DM recovery (96%), NDF (67%), and NFC concentrations (14%); however, silage treated with inoculant had greater CP (8.5 vs. 8.0%; P = 0.03), IVTD (56 vs. 54%; P = 0.01), and NDFD (53 vs. 51%, P = 0.02) and lesser ADF concentrations (38 vs. 40%; P = 0.02) than control. The inoculant did not affect (P > 0.05) silage pH (4.2) and lactic acid concentrations (1.5%) but resulted in greater acetic acid (2.5 vs. 2.0%; P = 0.01), propionic acid (1.6 vs. 1.0%, P < 0.01), and total acid concentrations (5.6 vs. 5.0%; P = 0.04), and decreased butyric acid (0 vs. 0.2%; P < 0.01), isobutyric acid (0.1 vs. 0.4%; P < 0.01), and NH3-N concentrations (4.4 vs. 5.3% N; P < 0.01). Aerobic stability (140 h), mold (1.1 log cfu/g) and yeast (2.2 log cfu/g) count were not affected (P > 0.05) by the inoculant treatment. At the genus level, there was no difference (P > 0.05) in relative abundance of Lactobacillus (85%), Enterobacter (4.0%), Enterococcus (1.8%), and Weissella (0.2%) between inoculant and control, but silage treated with inoculant had less Clostridium (1.0 vs. 2.3%, P = 0.04), Pediococcus (0.2 vs. 0.3%, P = 0.03) and greater relative abundance of Lactococcus (2.8 vs. 0.5%, P < 0.01) and Bacillus (0.2 vs. 0.1%, P = 0.01). At the species level, the inoculant was effective to increase the relative abundance of Lactococcus lactis (from 0.02 to 0.48, P = 0.002) and Lactobacillus buchneri (from 1.4 to 1.9, P = 0.03). SiloSolve FC is a promising microbial inoculant to be used in warm-season grass silage in subtropical and tropical regions.

2024-09-14·Journal of Animal Science

PSXI-27 Supplementing Bovacillus to feedlot cattle finished under heat stress conditions

作者: Pickett, Autumn ; Cooke, Reinaldo F ; Cappellozza, Bruno I ; Mackey, Shea

AbstractThis experiment compared performance, physiological, and carcass responses of finishing cattle receiving a Bacillus-based probiotic under heat stress conditions. Angus-influenced steers (n = 113) were purchased from an auction yard and assigned to the experiment [arrival body weight (BW) = 345 ± 2.7 kg]. On d 0, steers were ranked by initial BW and allocated to 1 of 20 drylot pens (5 or 6 steers/pen). Pens were randomly assigned to receive a finishing diet containing BOV (3 gּ animal-1ּ d-1 Bovacillus) or no additive (CON) until slaughter. Diets contained monensin but not tylosin. Steer BW was recorded on d 0, 28, 56, 84, 112, and at the time of shipping, which was considered final BW. Initial and final BW were used in average daily gain (ADG) calculation. Blood samples were collected immediately after BW assessment on d 0, 28, 56, 112 of the experiment as well as 8 d prior to slaughter. Plasma was analyzed for concentrations of alanine aminotransferase, aspartate transferase, alkaline phosphatase, gamma-glutamyl transferase, bilirubin, and blood urea nitrogen. Real-time temperature and humidity were recorded every hour for the duration of the trial for temperature-humidity index (THI) assessment. Steers were shipped to a packing facility (Tyson; Amarillo, TX) in 3 groups according to BW, which contained an equal number of pens from both treatments. Upon slaughter, hot carcass weight, backfat thickness, Longissimus muscle area, USDA marbling score, USDA yield and quality, and liver abscess score were recorded. The THI during the first and second thirds of the experimental period (79.8 and 78.1, respectively; SEM = 0.22) were substantially above the heat stress threshold (THI = 72). No treatment differences were recorded for BW parameters, ADG, or gain to feed ratio (P ≥ 0.21), despite a 10 kg increase in final BW and a 4 kg increase in hot carcass weight in BOV steers. Dry matter intake did not differ among treatments (P = 0.48). No treatment differences were recorded for carcass quality response, although incidence of liver abscess was reduced in BOV compared with CON groups (7.3 vs 19.0%; P = 0.04). A treatment × day interaction was detected (P = 0.02) for plasma concentration of GGT, which tended (P = 0.08) to be greater for CON vs. BOV steers on d 56. No other treatment differences were detected for plasma metabolites (P ≥ 0.69). Collectively, BOV supplementation mitigated the incidence of liver abscesses in finishing cattle, whereas improvements to steer performance were only numerical.

204

项与 Novozymes A/S 相关的新闻（医药）

2025-04-29

·医药健闻

美敦力前高管担任奥林巴斯新CEO；默克宣布39亿美元收购SpringWorks；诺和诺德赢得重大法律胜利 | 日报

全球医疗行业每日重点资讯文 | 苏丁企业动态奥林巴斯公司（Olympus）董事会一致决定任命美敦力前执行副总裁兼内外科产品组合总裁Bob White接替奥林巴斯董事、代表执行官、总裁兼首席执行官Yasuo Takeuchi，自2025年6月1日起生效。Bob还将在定于2025年6月举行的奥林巴斯股东大会上被提名为董事会候选人。在加入美敦力之前，Bob曾在GE医疗、Merge Healthcare和IBM医疗保健部门担任领导职务。德国医疗保健和材料集团默克(Merck KGaA)周一表示，已达成协议，将以39亿美元的股权价值收购美国生物技术公司SpringWorks Therapeutics，以加强其抗癌药物业务。SpringWorks总部位于美国康涅狄格州的斯坦福德，于2019年在纽约上市。该公司开发治疗癌症和罕见肿瘤的药物，目前在市场上有两种产品。诺和诺德(Novo Nordisk)取得了一场重大的法律胜利，这在很大程度上限制了配制药店营销或销售该制药商的畅销减肥药维格威(Wegovy)和糖尿病治疗药物奥泽美匹克(Ozempic)的更便宜且未经批准的仿制版本。得州联邦法官周四晚间作出关键裁决，驳回了复合药房行业协会的初步禁令申请，维持美国食品药品监督管理局(FDA)关于糖尿病药物Ozempic和减肥药Wegovy活性成分司美格鲁肽(semaglutide)“供应短缺状态已结束”的认定。安进（Amgen）正在加倍扩大其在美国的生产业务，并计划对其位于俄亥俄州中部的工厂进行重大升级。安进表示，该公司将投资9亿美元扩建其位于俄亥俄州新奥尔巴尼的生物制造工厂。该项目预计将使该州的安进的工作岗位总数达到750个，并将公司在俄亥俄州的总投资增加到14亿美元以上。艾伯维计划未来十年内在美国投资数十亿美元，目标是到2035年在美国投资100亿美元，以支持其当前的增长计划，并扩展到肥胖等新领域。这笔款项的一部分将专门用于建造四个新的美国生产设施，专门用于活性药物成分（API）、药品、肽和设备。赛默飞世尔科技（Thermo Fisher Scientific）表示，未来四年将在美国额外投资20亿美元。承诺的四分之三资金将支持赛默飞世尔的制造业务，而剩余的5亿美元将扩大其研发工作。赛默飞世尔已经拥有由64个美国工厂组成的广泛网络，覆盖37个州。该公司在其他43个国家也有业务。截至去年年底，该公司的全球员工人数约为125,000人，其中超过50,000人在美国工作。4月28日，恒瑞医药宣布，其发行H股计划正式获得中国证监会备案，拟发行不超过8.15亿股普通股赴港上市。这是继2000年A股上市后，恒瑞首次通过股权融资“补血”，也是其国际化战略的关键一步。依据此前披露的IPO计划，若成功登陆港股，恒瑞拟将募资20亿美元（约145亿元人民币）主要用于海外研发中心建设、全球多中心临床试验及国际化销售网络扩张。首药控股拟以自有及自筹资金不超过7.87亿元，在亦庄新城国际医药创新公园（BioPark）自主建设新的“首药控股新药研发与产业化基地”项目，并与北京经济技术开发区管委会签署《经济发展合作协议》。该合作协议生效后，公司将按照招拍挂供应程序取得项目宗地，建设包括研发中心、质控中心、临床试验中心、销售中心及生产基地在内的公司新总部，建设期3年。科源制药公告，拟收购山东宏济堂制药集团股份有限公司99.42%股权，交易作价约35.81亿元。同时拟定增募资不超7亿元。宏济堂是国内知名的阿胶产品生产企业。宏济堂与科源制药均为“力诺系”旗下公司，二者实控人均为高元坤。科源制药2023年4月登陆创业板上市，主要从事化学原料药及其制剂产品的研发、生产和销售。康弘药业公告，公司全资子公司北京康弘生物医药有限公司拟吸收合并北京弘健医疗器械有限公司、四川康弘中药材种植有限公司拟吸收合并成都康弘医药贸易有限公司、四川济生堂药业有限公司拟吸收合并四川济生堂兴尚生物科技有限责任公司。吸收合并后，北京康弘生物、康弘种植、济生堂存续经营，公司名称、股权结构保持不变。产业动态美敦力（Medtronic）宣布与Dragonfly Endoscopy达成战略合作，正式将后者研发的Dragonfly胰胆内窥镜系统引入美国市场。这一协议标志着胰胆疾病诊疗领域数十年来首次迎来重大技术升级。根据协议，美敦力将于2024年内率先在美国20家顶尖学术医疗中心及综合性医院启动Dragonfly系统的临床应用，未来三年逐步覆盖全美。美敦力宣布，其自主研发的全球最小直径无腔除颤导线OmniaSecure正式获得美国食品药品监督管理局（FDA）批准，用于右心室植入治疗危及生命的心律失常疾病。波士顿科学宣布，针对FARAPULSE脉冲电场消融（PFA）系统和辅助使用FARAPOINT PFA导管治疗持续性心房颤动（AF）患者的ADVANTAGE AF临床试验第二阶段达成12个月的主要安全性和有效性终点。该研究的主要结果已在圣地亚哥举行的第二届PFA现场手术峰会上公布，并同时在《Circulation》杂志上发表。益普生与上药控股有限公司达成战略合作协议。双方将围绕达菲林展开合作，通过加强资源整合和渠道覆盖，进一步推动达菲林产品在中国市场的深度覆盖。达菲林作为常用的促性腺激素释放激素类药物（GnRHa），在前列腺癌、中枢性性早熟、子宫内膜异位症、女性不孕症、子宫肌瘤的术前治疗等多种疾病中被广泛应用。复星医药控股子公司复宏汉霖与Alvogen Korea签订《许可协议》，复宏汉霖授予Alvogen Korea于许可区域（即韩国）及领域（即广泛期小细胞肺癌（ES-SCLC）、非鳞状非小细胞肺癌（nsNSCLC）、转移性结直肠癌（mCRC）、胃癌（GC）和食管鳞状细胞癌（ESCC）适应症）独家商业化斯鲁利单抗注射液的权利。Alvogen Korea应就许可产品向复宏汉霖支付至多1450万美元。基于许可产品于许可区域的年度净销售额达成情况，Alvogen Korea应依约向复宏汉霖支付至多9750万美元的商业销售里程碑款项。易瑞生物公告，公司与Chr. Hansen A/S（科汉森）签署合同，约定的2025-2029年度销售目标合计为7305.77万欧元，折合约6.01亿元人民币。合作内容包括公司在指定区域内授权科汉森独家销售、分销及推广公司产品，主要产品为乳中抗生素残留筛查测试、黄曲霉毒素M1筛查及定量测试、三聚氰胺及乳清掺假测试等。合同自2025年6月16日起生效，持续有效期为5年。以岭药业公告，公司全资孙公司万洋衡水制药有限公司提交的“来曲唑”化学原料药上市申请已获国家药品监督管理局批准。来曲唑是一种高效、选择性非甾体类芳香化酶抑制剂，用于乳腺癌治疗。君实生物宣布，由公司自主研发的抗PD-1单抗药物特瑞普利单抗注射液（拓益®）用于不可切除或转移性黑色素瘤的一线治疗的新适应症上市申请于近日获得国家药品监督管理局（NMPA）批准。这是特瑞普利单抗在中国内地获批的第12项适应症。信达生物宣布，第三代表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）靶向药物奥壹新（利厄替尼片）的新药上市申请获得国家药品监督管理局批准，用于具有表皮生长因子受体（EGFR）外显子19缺失（19DEL）或外显子21置换突变（L858R）的局部晚期或复发转移性非小细胞肺癌（NSCLC）成人患者的一线治疗。奥壹新（利厄替尼片）是目前唯一获批上市的，以萘胺结构为基础的第三代EGFR-TKI药物。清华人工智能医院正式揭牌成立，建设将分阶段进行，初期将在清华AI全面布局和多学科医工交叉的基础上，建设AI医院系统，依托北京清华长庚医院及北京清华长庚互联网医院试运行，以全科医学科和眼科、放射诊断科、呼吸科等专科为试点。未来，将构建“AI+医疗+教育+科研”生态闭环，促进优质医疗资源的高效扩容与均衡布局。联系美通社+86-10-5953 9500info@prnasia.com

高管变更IPO并购

2025-04-24

·PRNewswire

Novo Holdings and EIFO invest €48 million in HealthCap IX to strengthen the Nordic life sciences ecosystem

COPENHAGEN, Denmark, April 24, 2025 /PRNewswire/ -- Novo Holdings and the Export and Investment Fund of Denmark (EIFO) have jointly invested €48 million in HealthCap IX, a Swedish life sciences venture fund focused on building innovative companies in areas of high unmet medical need. Following the investment, HealthCap will establish a local presence in Copenhagen at the BioInnovation Institute (BII) to increase its focus on Nordic investment opportunities. In particular, the fund has committed to supporting early-stage companies emerging from academic and corporate research environments, with the aim of helping them progress towards further financing. HealthCap is a longstanding and recognised venture firm with a strong presence in the Nordics. Since its founding in 1996, it has built a strong track record of supporting companies that address serious medical conditions through novel therapeutic approaches. With investments in more than 130 companies, HealthCap has played a central role in developing over 30 approved pharmaceutical products and more than 50 innovative medical technologies – benefitting millions of patients globally. HealthCap's focus is on precision medicine and therapies targeting areas of high unmet medical need, which aligns closely with the strategy of Novo Holdings' Seed Investments vertical. The Seed Investments team at Novo Holdings backs early-stage biotech companies emerging from strong science, often at the point of spinout from academic institutions. HealthCap's expertise in identifying and supporting such companies through their growth journey makes the fund a natural partner. This marks EIFO's first investment with HealthCap, while Novo Holdings has previously backed earlier HealthCap funds. Mårten Steen, Managing Partner, HealthCap, said: "We are proud to welcome two of Denmark's most respected investors as LPs in HealthCap IX. The investments from Novo Holdings and EIFO not only enhance HealthCap's ability to support transformative healthcare companies but also reinforce the Nordic region's position as a global leader in life science innovation and entrepreneurship." Daniel Rasmussen, Principal, Seed Investments, Novo Holdings, said: "We are pleased to continue our collaboration with HealthCap, which over many years has proven to be a strong partner in advancing the next generation of healthcare solutions. With this commitment, we aim to support high-quality scientific projects in the Nordics and ensure they have the support needed to develop into well-structured companies with clinical and commercial success." Rikke Michaela Greve, Investment Manager, EIFO, added: "With its strong track record, good reputation, and well-established network in Denmark, HealthCap is a key player and a local anchor for Danish life sciences. It has the ability to attract international investment and collaboration, which is vital to securing sufficient funding for the region." About HealthCap HealthCap is a leading European venture capital firm investing globally in life sciences. Since its founding in 1996, HealthCap has raised multiple funds and invested in more than 130 companies developing innovative solutions in areas of high unmet medical need. The firm focuses on precision medicine and breakthrough therapeutics, with more than 30 pharmaceutical products approved and over 50 medical technologies developed. HealthCap is headquartered in Stockholm, Sweden, and plays an active role in supporting life sciences across the Nordic region. About EIFO – Denmark's Export and Investment Fund EIFO is Denmark's national promotional bank and official export credit agency. The organisation works to open doors for global business, accelerate the green transition, support innovative technologies, and contribute to Denmark's economic security. With total commitments exceeding DKK 170 billion and activities in more than 100 countries, EIFO offers financial solutions to Danish businesses and their global partners. It is also Denmark's largest venture investor, making 78 investments in companies and 16 in funds in 2024. About Novo Holdings A/S Novo Holdings is a holding and investment company responsible for managing the assets and wealth of the Novo Nordisk Foundation. The purpose of Novo Holdings is to improve people's health and the sustainability of society and the planet by generating attractive long-term returns on the assets of the Novo Nordisk Foundation. Wholly owned by the Foundation, Novo Holdings is the controlling shareholder of Novo Nordisk A/S and Novonesis A/S (formerly Novozymes A/S) and manages an investment portfolio with a long-term return perspective. In addition to managing a broad portfolio of equities, bonds, real estate, infrastructure, and private equity assets, Novo Holdings is a world-leading life sciences investor. Through its Seed, Venture, Growth, Asia, Planetary Health, and Principal Investments teams, Novo Holdings invests in life sciences companies at all stages of development. As of year-end 2024, Novo Holdings had total assets of EUR 142 billion. SOURCE Novo Holdings WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

2025-03-26

·PRNewswire

Novo Holdings participates in €23 million Series A for Tribune Therapeutics to advance next-generation anti-fibrotic therapies

Investment addresses the need for disease-modifying therapies targeting the root causes of fibrosis Funding will support the advancement of CCN family inhibitor TRX-44 into clinical trials for treatment of fibrotic conditions including idiopathic pulmonary fibrosis (IPF) Novo Holdings and HealthCap co-created Tribune in 2020 COPENHAGEN, Denmark, March 26, 2025 /PRNewswire/ -- Novo Holdings today announced its participation in a €23 million Series A round for Tribune Therapeutics ('Tribune'). The round was led by new investor LifeArc Ventures and joined by Novo Holdings, HealthCap, Innovestor's Life Science Fund and Inven2 as well as new Series A investors Industrifonden and Investinor. Tribune Therapeutics was co-founded in 2020 by the Seed Investments team of Novo Holdings and HealthCap Ventures to create broadly applicable disease-modifying therapies for fibrotic diseases by targeting downstream, tissue-agnostic gatekeepers of scar formation and tissue remodelling. Through a Pioneer Innovator Grant, the Novo Nordisk Foundation – whose assets Novo Holdings manages – partially funded scientific discoveries at the Oslo University Hospital by Professor Håvard Attramadal and Ole J. Kaasbøll that led to Tribune's formation. The Pioneer Innovator grant programme is designed to advance science-based discoveries in sustainability and health by funding experiments and activities that push ideas toward proof-of-concept and beyond, in line with Novo Nordisk Foundation's vision of improving people's health and the sustainability of society and the planet. Tribune's lead programme, TRX-44, is currently in development for the treatment of fibrotic conditions including idiopathic pulmonary fibrosis (IPF). TRX-44 prevents scar formation by mimicking the structure and function of CCN5. CCN5 is an endogenous protein that naturally blocks the pro-fibrotic effects of other CCN family members, including CTGF/CCN2 and WISP1/CCN4, on multiple cell types contributing to fibrotic pathology. João Ribas, PhD, Principal of Novo Holdings, said: "Tribune's scientific founders have discovered key insights into the mechanism of action of CCNs, leading to an elegant and powerful approach to harness the biology of CCNs to shut down a key pro-fibrotic pathway. The novel path being advanced by Tribune holds potential for meaningfully impacting the treatment of multiple devastating and often terminal fibrotic indications." Georg Vo Beiske, PharmD, Tribune Chief Executive Officer and HealthCap Venture Partner, said: "Tribune's foundational science has far-reaching therapeutic potential, and Novo Holdings has been a great partner in bringing the company to fruition through its early support and extended network. As we advance toward the clinic, having the backing of such a strong investor group increases our confidence in our innovative approach to treat fibrotic diseases." About Tribune Therapeutics Tribune Therapeutics is a biotechnology company advancing novel medicines to treat fibrosis, regardless of the cause, tissue or diagnosis. The company was founded on groundbreaking structural insights into the CCN family of proteins, key drivers of scar formation that have historically been difficult to comprehensively target. Tribune is advancing multiple programs, including CCN5 mimic TRX-44. For more information, visit or follow us on LinkedIn. About Novo Holdings A/S Novo Holdings is a holding and investment company that is responsible for managing the assets and the wealth of the Novo Nordisk Foundation. The purpose of Novo Holdings is to improve people's health and the sustainability of society and the planet by generating attractive long-term returns on the assets of the Novo Nordisk Foundation. Wholly owned by the Novo Nordisk Foundation, Novo Holdings is the controlling shareholder of Novo Nordisk A/S and Novonesis A/S (Novozymes A/S) and manages an investment portfolio with a long-term return perspective. In addition to managing a broad portfolio of equities, bonds, real estate, infrastructure and private equity assets, Novo Holdings is a world-leading life sciences investor. Through its Seed, Venture, Growth, Asia, Planetary Health and Principal Investments teams, Novo Holdings invests in life science companies at all stages of development. As of year-end 2023, Novo Holdings had total assets of EUR 149 billion. About the Novo Nordisk Foundation Established in Denmark in 1924, the Novo Nordisk Foundation is an enterprise foundation with philanthropic objectives. The vision of the Foundation is to improve people's health and the sustainability of society and the planet. The Foundation's mission is to progress research and innovation in the prevention and treatment of cardiometabolic and infectious diseases as well as to advance knowledge and solutions to support a green transformation of society. SOURCE Novo Holdings WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

100 项与 Novozymes A/S 相关的药物交易

登录后查看更多信息

100 项与 Novozymes A/S 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

或

查看完整样例数据

管线布局

2025年05月25日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

临床前

其他

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

Plectasin	金黄色葡萄球菌感染更多	临床前
PV-704	骨质疏松症更多	终止
PV-802	短肠综合征更多	终止
PV-905	肝病更多	终止
PV-801	创伤和损伤更多	终止